CTIX Stock Updates 08/26/2014 13:28:14 $CTIX Yes, he did.

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
CTIX Stock Updates 08/26/2014 13:28:14 $CTIX
Yes, he did. Well sort of...
As I recall he said (sometime in early 14) that he might run the tests after cohort 7.

Then he more recently said something to the effect that he intends to ask for those tests after this (c8) cohort.

I don't expect to see much detail for K until after R&R.
Of course, I am on the record for being all in favor of being wrong on that point.

He!!s bells, if they give us B anytime in next 2 months this should take off. MTA, BOD, K&P after that
Another possibility is you may be reading too much into study completion dates, much as some of us, me included did when the completion date was November 2013. Currently, IMO as I don't know for sure, the study completion dates for primary outcomes are pushing forward with each new cohort accounting for MTD final cohort. The primary outcomes and that data is included in the final data date for November. Secondary outcomes would be collected 6 months after the final doses of the last cohort, the expanded cohort establishing MTD.

Even if Cohort 8 establishes dose limits, Cohort 9 will roll back to 165 mg/m2 and enroll 6. If 1 or less experiences a dose limiting toxicity then then there will be one more confirmation cohort of up to 12 patients. This extends the study for primary outcomes another 6 months and makes the total number of cohorts 10. As stated below, if one or more of the patients shows a DLT, then that becomes the maximally administered dose and the final cohort is rolled back to the level of cohort 6.

"Primary Outcome Measures:

Maximum Tolerated Dose (MTD) of Kevetrin [ Time Frame: up to 6 months ] [ Designated as safety issue: Yes ]

A dose will be declared the MTD if at least 1 patient out of 6 patients experience a dose limiting toxicity (DLT) at the highest dose level below the maximally administered dose. Once an MTD has been established, up to 12 additional patients may be enrolled at the MTD dose level for confirmation of safety.

The maximally administered dose is if 1 or more of 6 patients experience a DLT."

I hope everyone sees now why I truly hope the DLT does not occur in cohort 8, but cohort 9 or later. A safe cohort 8 all but assures an MTD above 200 mg/m2 and well above the anticipated efficacy range of 100 to 200 mg/m2.

http://www.clinicaltrials.gov/ct2/show/NCT016...amp;rank=1

CTIX Stock Message Board http://investorshangout.com/Cellceutix-Corpor...TIX-87375/

A wise man once said...

Quote:
The Catalyst News Cycle tends to render technical analysis as useless as teats on a Boar Hog from time to time. The release of P21 data WILL BE one of those times


R&R.
leo and menon are not going to R & R to exchange strudel recipes. leo and especialy menon would not say anything about updating info on the compounds unless he had something. at least that has not been his history. it just depends if dr menon can shake his minders. i love good news seems some people have trouble tolerating it or want to shave cents off the share price.


CTIX is showing real strength given the run to date. Given Leo's PRs and the stock movement, I'm expecting good news from the RR presentation.

That said, I'm not nearly as sanguine about the general market and economy. I just initiated several short positions in technology (supply chain mostly and memory manufactures). I think the market is WAY overvalued and we're coming into the two worst months for the market.

Even with a market dislocation (my opinion only), I expect CTIX to be resilient and with good news to preform very well.

Should be an interesting few months! Good thing football season is here to take some of my attention of the markets


HA! I keep wondering if I will have the cajones to get up there and speak to L and M. We'll see. Being a small time investor, I think I'd rather they spend their time with real investors.
well you are going to find out aren't you? if menon is there you will.
or a .02 cent drop =(
That's what I'm thinking too...
It looks like lunch is over and trading will commence. We are very likely to see what action above $2.10 looks like.
Soon.

Go CTIX!
I keep having to circle back to the latest change in primary completion dates and study completion dates on clinicaltrial.gov. In the past they always extended the dates by about 6 months, leaving a 6 month gap between (ex. Primary completion April 2014, study completion Oct 2014) we assumed this 6 month gap was for a final cohort at MTD for up to 12 patients.

The last change has September as the Primary completion date. If you put any weight towards that date, it means they expect to reach DLTs in September, start of cohort 9 (my guess was cohort 10 based on my rudimentary calculations). Fine. But why is the study completion date November? That doesn't add up to me. That would mean there is no final cohort at MTD (because it would take 6 months per the protocol).

To me this means one of two things: Either they are really bad with dates/don't care about what's published here because it will just change at a future date OR something else is brewing, like they have enough data to move forward onto future trials. That is the K elephant in the room for me.
Thanks Karin.
Your friend needs to call his brokerage and have his account limits adjusted. Many accounts have a default setting that limits certain types of trades on new accounts. Some can't trade penny stocks, some can't trade options. Some have limits on size of trade. Some don't allow pre and post market. Some only allow pre market at 6am eastern while others allow 4am eastern. Just have him call the broker and adjust his preferences.

Most can be adjusted with a phone call except for Options trading which might require some additional paperwork. That can usually be done online.



In Reply to 'jok'
Question for the board; i have a friend who is trying to buy some shares this morning he says his brokerage won't let him put in an order for more than 10,000 shares. Is that possible?

Thanks

jok

i hope shrinkage and MTD so we can open this trial up in phase 2. people in desperate need. some that have posted on this board that are now gone. and don't forget babies with retinoblastoma. breakthrough and orphan.


Leo said they were running P21 after the last cohort.

I'm getting a bit excited about R@R 2014 coming up. I am planning on attending. In reviewing last year's presentation, I can read this line over and over and over...

"•Kevetrin activated p21 in 4 out of 5 patients treated with 20 or 30 mg/m2"

What will we learn this year?
It looks like someone is trying to cap it at $2.10 ...
I think this is going up to at least 2.15 today
That would be epic!
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 118

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 100

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 95

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 76

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading
Franklin County Trees Raise Funds and Honor Veterans

Updated Category News Views 66

Holiday charity works best when it gives people something tangible to gather around, and Franklin County has found a pretty sturdy version of that formula. Its eighth annual Festival of Trees opens at 4 p.m. Saturday, November 21, at the Franklin County 11/30 Visitors Center in downtown Chambersburg, carrying the theme A Salute To Veterans. More than 80 decorated trees...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 89

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight

Updated Category News Views 87

Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 50

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading

Top 5 Most Recently Viewed Articles

Sigenergy Embraces AI in Smart Energy Solutions at Intersolar

Updated Category News Views 284

Sigenergy's Vision for Smart Energy Sigenergy recently showcased its dedication to innovative, AI-driven energy solutions during a major event at Intersolar 2025. This milestone reinforced the company's mission to develop a user-centered smart energy ecosystem. With over 500 attendees, the launch at Brainlab Tower highlighted Sigenergy's ambitious goal of redefining...

Continue Reading
Investor Insights on Charter Communications Earnings Report

Updated Category News Views 181

Anticipation Surrounding Charter Communications Earnings Charter Communications (NASDAQ: CHTR) is set to unveil its quarterly earnings in the near future. Investors are particularly eager to see if the company can surpass previous estimates and provide favorable outlooks for the upcoming quarters. Recent trends suggest that beat expectations could lead to positive stock...

Continue Reading
Intevac Welcomes Kevin Barber as New Chairman of the Board

Updated Category News Views 362

Intevac got hit with a leadership shakeup back in early 2024 when Kevin Barber took the reins as the new Board Chairman, stepping into some big shoes after David Dury. Traders were buzzing—who wouldn’t be? Dury had been at the helm since 2017, steering Intevac through several crucial transitions. But Barber's appointment felt like a fresh shot of adrenaline for...

Continue Reading
Insight Into the Growing Market for Display Cases Worldwide

Updated Category News Views 63

The Growing Popularity of Display Cases in Global Markets As retail continues to evolve, display cases have become essential for attracting customers. Their visual appeal significantly affects buying choices, leading businesses to invest in high-quality display options. Recent research shows that the demand for display cases is on the rise, with an expected annual growth...

Continue Reading
Medallion Secures $43 Million to Innovate Healthcare Credentialing

Updated Category News Views 347

Medallion Announces Major Funding to Revolutionize Credentialing Medallion has successfully raised $43 million to further develop its innovative AI-driven platform and to launch CredAlliance™, a groundbreaking credentialing clearinghouse aimed at streamlining provider onboarding and verification processes. Empowering Healthcare with Intelligent Automation With this new...

Continue Reading